| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CD40 cell line, luciferase reporter, CD40 NF-kB cell line, NFkB cell line |
| Product Type | |
| Shipping | |
| Species | |
| Storage |
Scientific Background
CD40, a TNF receptor superfamily member, was initially identified on B lymphocytes. Antigen presenting cells (APCs) such as monocytes, basophils, dendritic cells, have been found to express CD40. Additionally, CD40 has been identified in non-immune cells such as endothelial cells and epithelial cells. A wide variety of carcinoma cells over-express CD40 as well. Interaction with CD40 ligand (CD40L, CD154) on CD4+ T helper lymphocytes triggers the expression of intercellular adhesion molecule (ICAM) and other pro-inflammatory cytokines. CD40:CD40L signaling simultaneously increases activation of antigen-specific T cells. CD40 activates NF-κB-dependent signaling in response to lipopolysaccharide (LPS) found on Gram negative bacterial pathogens. Furthermore, agonistic CD40 monoclonal antibodies have been shown to activate antigen presenting cells (APC) and promote anti-tumor T-cell responses in addition to fostering cytotoxic myeloid cells with the potential to control cancer in the absence of T-cell immunity.
Product Description
ImmunotherapyRecombinant HEK293 cell line expressing full length human CD40 (Tumor necrosis factor receptor superfamily member 5; TNFRSF5). Expression is confirmed by flow cytometry and Western Blot. This NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD40 ligand, NF-κB transcription factor binds to the DNA response elements to induce transcription of the luciferase gene.
Product Specifications
| Host Cell Line | HEK293 |
|---|---|
| Host Species | Human |
| Transfection Method | Lipofectamine 2000 |
| Format | Each vial contains ~2 x 106 cells in 1mL of 10% DMSO in FBS. |
| Harmonized Tariff Code | 3002-5900 |
Quality Control & Validation
✓ Mycoplasma-TestedThis cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, Cat. #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, Cat. #LT07-518) was used as a positive control.
Usage Notes
See data sheet for detailed culturing and assay protocol.
Safety & Handling
⚠ Avoid freeze/thaw cycles.
Regulatory Information
License Disclosure
Related Products
Related Products: Cat. #71191, 79528, 60690, 60187
Required Accessories: Cat. #79528,60690,60187,79796
This product is engineered on a HEK293 background (Human origin). The HEK293 host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.
This product is classified as BSL-2. Work must be performed in a certified BSL-2 laboratory by trained personnel. All procedures that may generate aerosols must be conducted inside a Class II Biological Safety Cabinet. Institutional Biosafety Committee (IBC) approval is required before use.
Yes. This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, Cat. #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, Cat. #LT07-518) was used as a positive control. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.
Store this product at Liquid Nitrogen. Specifically: Immediately upon receipt, store vials in liquid nitrogen. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.
This stable cell line was generated using Lipofectamine 2000 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Li G et.al. (2013) Human Genetics in Rheumatoid Arthritis Guides a High-Throughput Drug Screen of the CD40 Signaling Pathway. PLoS Genet. 9: e1003487.
- Pontrelli P et.al. (2006) CD40L Proinflammatory and Profibrotic Effects on Proximal Tubular Epithelial Cells: Role NF-κB and Lyn. J. Amer. Soc. Neph. 17: 627.
- Lavorgna A et.al. (2014) A Critical Role for IL-17RB Signaling in HTLV-1 Tax-Induced NF-κB Activation and T-Cell Transformation. PLoS Path. 10: e1004418.
- Moschonas A et.al. (2012) CD40 Stimulates a "Feed-Forward" NF-κB- Driven Molecular Pathway That Regulates IFN-β Expression in Carcinoma Cells. J. Immunol. 188: 5521.